The drugmaker’s new Cambridge research hub combines nearly 2,000 researchers with robotics, continuous automation and agentic AI. It offers an early look at how automation could change scientific work without simply eliminating the scientist.
AstraZeneca’s newest research center puts a different version of workplace automation inside one of the most highly skilled environments in the economy. The pharmaceutical company opened a 570,000-square-foot, 18-story research and development center in Cambridge, Massachusetts, as part of more than $1 billion in investment in the state. Ten floors are devoted to interconnected laboratories equipped with robotics, continuous automation and agentic artificial intelligence. Together with AstraZeneca’s nearby genomic medicine facility, the Kendall Square operation is expected to house nearly 2,000 researchers and scientists working on cancer, chronic diseases, rare diseases, cell therapies and biologics.
The robots are not simply moving boxes around a pharmaceutical warehouse. According to reporting by the Boston Globe, AstraZeneca is using automation within the process of conducting experiments itself. That places the Cambridge facility inside a broader change in automation: machines are increasingly being designed to perform portions of knowledge work that previously depended on highly trained employees. In this case, automation can execute repetitive laboratory processes while scientists determine what questions to investigate and interpret what the experiments produce.
The Laboratory Is Becoming an Automated Workplace
AstraZeneca describes the facility as integrating robotics, continuous automation and agentic AI rather than treating those technologies as separate tools. That combination is important. Traditional laboratory automation can execute predefined procedures repeatedly; more autonomous systems potentially allow software to coordinate multiple steps and instruments across an experimental workflow. The company’s own hiring provides another window into how that changes the work. A recent Cambridge opening seeks a hybrid bench scientist/automation engineer who can translate scientific workflows into automated ones and work across laboratory science, robotics, data engineering and software development.
The position illustrates something that gets lost when automation is framed only as a question of jobs disappearing. AstraZeneca is looking for workers who understand both the experiment and the machine conducting portions of it. Its job description calls for experience creating and troubleshooting robotic methods and developing automated systems for high-throughput production, screening and characterization of antibody therapeutics. The emerging job is therefore not simply “scientist” or “automation engineer.” It sits between the two.
That could alter the economics of pharmaceutical research as much as the individual job description. Drug discovery involves enormous numbers of experiments, many of which require repetitive preparation, screening and analysis. Automation can increase the number of experiments that laboratories can run while improving consistency and allowing experiments to continue without requiring a researcher to physically perform every step. Scientists can spend more of their time designing experiments, analyzing results and deciding what should happen next.
More Automation, but More Hiring Too
The Cambridge opening also complicates the assumption that introducing robots necessarily means reducing headcount. AstraZeneca currently employs roughly 2,000 people in Massachusetts and expects that number to reach about 3,000 within the next several years, increasing its workforce in the state by more than 50 percent. The new center itself is expected to have about 1,100 employees by the end of 2026, according to the Boston Globe.
That does not mean automation will have no workforce consequences. It suggests the first effect may be a change in the composition of scientific work. Laboratory employees increasingly may need some combination of biology, engineering, automation, software and data skills. AstraZeneca’s automation-engineer posting already asks candidates to collaborate with scientists, data engineers and software developers while converting laboratory processes into scalable automated systems.
The expansion is occurring during an unsettled period for biotechnology. The industry has spent several years dealing with weaker investment and pressure on research funding, even as pharmaceutical companies race to improve the speed and economics of drug development. AstraZeneca is making the Cambridge investment as part of a much larger $50 billion U.S. investment program, while targeting $80 billion in annual revenue by 2030.
Automation Is Moving Up the Skills Ladder
For years, the automation debate centered on factories, warehouses, customer-service centers and administrative offices. AstraZeneca’s Cambridge laboratory pushes the conversation further up the skills ladder. These are experiments being conducted inside a major pharmaceutical R&D operation by systems working alongside people with advanced scientific training.
The more useful question may therefore be less about whether robots replace scientists than which parts of being a scientist remain distinctly human once machines can perform more of the experimental process. AstraZeneca’s answer, at least for now, appears to be more scientists working with more automation—not fewer scientists working without it. Its billion-dollar Cambridge facility turns that proposition from a prediction about the future of work into something already being built inside the laboratory.
Sources: AstraZeneca’s announcement and facility details · Boston Globe reporting on the opening and robotics · Reuters on AstraZeneca’s $1 billion Massachusetts investment · AstraZeneca’s scientist/automation engineer position